Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone

Psychopharmacology (Berl)
July 2010
https://pubmed.ncbi.nlm.nih.gov/20386884/

Rationale: Prescription opioid abuse has risen dramatically in the United States as clinicians have increased opioid prescribing for alleviation of both acute and chronic pain. Opioid analgesics with decreased risk for abuse are needed.

Friday afternoon Q & A (2017 Conference) (LDN, low dose naltrexone)

Questions on use of LDN in psoriasis, Lyme Disease, cancer, thyroid, diabetes, Crohn’s, MS, Lyme, vitiligo, other autoimmune diseases, administration route, dosing, nutrition, environmental toxins, LDN receptors, thymus proteins, peptides, stem cells, Vitamin D, insurance coverage for LDN, resources for testing and other treatments.

Saturday afternoon Q & A (2017 Conference) (LDN, low dose naltrexone)